Chandra Bhagat Pharma Ltd
₹ 69.0
-3.48%
14 Nov
- close price
About
Incorporated in 2003, Chandra Bhagat Pharma Ltd manufactures and trades Pharmaceutical Formulations and API Products[1]
Key Points
- Market Cap ₹ 52.1 Cr.
- Current Price ₹ 69.0
- High / Low ₹ 160 / 63.0
- Stock P/E 33.0
- Book Value ₹ 39.4
- Dividend Yield 0.00 %
- ROCE 7.95 %
- ROE 5.42 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 115 days to 60.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.97% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.7.39 Cr.
- Debtor days have increased from 49.4 to 65.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
35 | 48 | 61 | 80 | 90 | 97 | 106 | 94 | 71 | 94 | 120 | 221 | 167 | |
35 | 46 | 58 | 76 | 85 | 92 | 102 | 91 | 67 | 91 | 116 | 228 | 170 | |
Operating Profit | 0 | 2 | 3 | 3 | 4 | 5 | 5 | 3 | 4 | 3 | 3 | -7 | -3 |
OPM % | 1% | 4% | 5% | 4% | 5% | 5% | 4% | 3% | 5% | 3% | 3% | -3% | -2% |
0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 11 | 7 | |
Interest | 0 | 2 | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 1 | 2 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Profit before tax | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 2 |
Tax % | 27% | 17% | 39% | 51% | 27% | 33% | 22% | 26% | 32% | 27% | 22% | 33% | |
0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | |
EPS in Rs | 9.60 | 8.37 | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 2.09 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 16% |
3 Years: | 46% |
TTM: | -14% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 17% |
3 Years: | 100% |
TTM: | 35% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 0% |
1 Year: | -40% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 3% |
3 Years: | 4% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.25 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 3 | 6 | 6 | 6 | 7 | 8 | 14 | 18 | 18 | 19 | 20 | 21 | 22 |
11 | 19 | 28 | 28 | 22 | 22 | 31 | 30 | 27 | 21 | 19 | 16 | 23 | |
9 | 7 | 8 | 10 | 26 | 28 | 37 | 19 | 19 | 25 | 14 | 56 | 42 | |
Total Liabilities | 24 | 32 | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 95 |
1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 1 |
23 | 31 | 41 | 44 | 51 | 56 | 78 | 74 | 71 | 72 | 60 | 99 | 92 | |
Total Assets | 24 | 32 | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 95 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 6 | |
0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 | -2 | |
0 | 0 | 0 | 0 | 8 | 7 | -4 | 7 | -6 | -10 | -4 | -6 | |
Net Cash Flow | 0 | 0 | 0 | 0 | -1 | -0 | -0 | -0 | 2 | 3 | 1 | -1 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 85 | 65 | 71 | 66 | 80 | 67 | 90 | 54 | 80 | 58 | 25 | 65 |
Inventory Days | 161 | 177 | 123 | 133 | 145 | 174 | 187 | 215 | 153 | 100 | 15 | |
Days Payable | 53 | 43 | 33 | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | |
Cash Conversion Cycle | 85 | 174 | 205 | 156 | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 |
Working Capital Days | 107 | 149 | 166 | 134 | 125 | 138 | 139 | 212 | 258 | 165 | 121 | 61 |
ROCE % | 2% | 12% | 10% | 10% | 15% | 17% | 13% | 7% | 7% | 9% | 7% | 8% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Be Held On November 13, 2024.
13 Nov - Board approved un-audited financial results for H1 2024.
-
Result For The Half Year Ended As On September 30, 2024.
13 Nov - Board approved un-audited financial results for H1 2024.
-
Board Meeting Intimation for Approval Of Unaudited Result For The Half Year Ended As On September 30, 2024
7 Nov - Notice of Board Meeting for Un-Audited Financial Statement.
-
Voting Result
2 Oct - Voting results of 21st AGM held on September 30, 2024.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
2 Oct - Scrutinizer’s Report on 21st AGM voting results.
Business Overview:[1][2]
Company manufactures formulations and does trading of API in domestic and international markets through its own distribution network and Sales force, under the brand name CBC.
It manufactures formulations by outsourcing to third party on job work basis
a) Major focus on Injection viz. ITV (Intravenous) & IM (Intramuscular), tablets and capsules supply to Hospital and Health care Centre for critical diseases
b) Getting approved formulations manufactured through Contract Manufacturers, Source & Supply of Generic and branded Pharma formulations and medicines to healthcare institution, Government, NGO’s, Hospitals & Distributors
c) Source, deal in Import, indenting and Supply in Specialty Chemicals, Intermediates & Active Pharmaceuticals Ingredients (API)